Leif Bergsagel, M.D., studies the molecular pathogenesis of multiple myeloma, a tumor of mature, isotype-switched plasma cells. It is a uniformly fatal malignancy that is frequently preceded by a common (1 percent of adults), benign preclinical phase known as monoclonal gammopathy of undetermined significance (MGUS).
Individualized risk-adapted therapy based on the patient's profile.
years treating myeloma: 25
Number of Myeloma Patients Treated Annually: 100-200
Details & contact info
Mayo Clinic Collaborative Research Building East Shea Boulevard
Scottsdale, AZ, United States, 85260
Send a message to Leif Bergsagel, MD